298 related articles for article (PubMed ID: 21907921)
1. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.
Taguchi A; Politi K; Pitteri SJ; Lockwood WW; Faça VM; Kelly-Spratt K; Wong CH; Zhang Q; Chin A; Park KS; Goodman G; Gazdar AF; Sage J; Dinulescu DM; Kucherlapati R; Depinho RA; Kemp CJ; Varmus HE; Hanash SM
Cancer Cell; 2011 Sep; 20(3):289-99. PubMed ID: 21907921
[TBL] [Abstract][Full Text] [Related]
2. [Proteome profiling for the identification of lung cancer signatures].
Cho WC
Zhongguo Fei Ai Za Zhi; 2012 Jul; 15(7):C4-7. PubMed ID: 23676999
[TBL] [Abstract][Full Text] [Related]
3. A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.
van Riel S; Thunnissen E; Heideman D; Smit EF; Biesma B
Ann Oncol; 2012 Dec; 23(12):3188-3189. PubMed ID: 23079729
[No Abstract] [Full Text] [Related]
4. Is proteomics starting to deliver on biomarkers discovery.
Admon A
Pigment Cell Melanoma Res; 2011 Dec; 24(6):1084-5. PubMed ID: 22216444
[No Abstract] [Full Text] [Related]
5. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Mack PC; Holland WS; Burich RA; Sangha R; Solis LJ; Li Y; Beckett LA; Lara PN; Davies AM; Gandara DR
J Thorac Oncol; 2009 Dec; 4(12):1466-72. PubMed ID: 19884861
[TBL] [Abstract][Full Text] [Related]
6. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
Chmielecki J; Pietanza MC; Aftab D; Shen R; Zhao Z; Chen X; Hutchinson K; Viale A; Kris MG; Stout T; Miller V; Rizvi N; Pao W
J Thorac Oncol; 2012 Feb; 7(2):434-42. PubMed ID: 22173702
[TBL] [Abstract][Full Text] [Related]
7. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
[TBL] [Abstract][Full Text] [Related]
8. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Karachaliou N; Costa C; Gimenez-Capitan A; Molina-Vila MA; Bertran-Alamillo J; Mayo C; Massuti B; Majem M; Carcereny E; Moran T; Sanchez JJ; Viteri S; Gasco A; Wannesson L; Souglakos J; Jimeno J; Rosell R;
J Thorac Oncol; 2013 Mar; 8(3):295-300. PubMed ID: 23407556
[TBL] [Abstract][Full Text] [Related]
9. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.
Brevet M; Johnson ML; Azzoli CG; Ladanyi M
Lung Cancer; 2011 Jul; 73(1):96-102. PubMed ID: 21130517
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
11. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Takezawa K; Pirazzoli V; Arcila ME; Nebhan CA; Song X; de Stanchina E; Ohashi K; Janjigian YY; Spitzler PJ; Melnick MA; Riely GJ; Kris MG; Miller VA; Ladanyi M; Politi K; Pao W
Cancer Discov; 2012 Oct; 2(10):922-33. PubMed ID: 22956644
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
13. Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.
Weaver Z; Difilippantonio S; Carretero J; Martin PL; El Meskini R; Iacovelli AJ; Gumprecht M; Kulaga A; Guerin T; Schlomer J; Baran M; Kozlov S; McCann T; Mena S; Al-Shahrour F; Alexander D; Wong KK; Van Dyke T
Cancer Res; 2012 Nov; 72(22):5921-33. PubMed ID: 22969147
[TBL] [Abstract][Full Text] [Related]
14. Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
Pan JB; Hou YH; Zhang GJ
Asian Pac J Cancer Prev; 2013; 14(2):695-700. PubMed ID: 23621221
[TBL] [Abstract][Full Text] [Related]
15. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
[TBL] [Abstract][Full Text] [Related]
16. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
Amann JM; Lee JW; Roder H; Brahmer J; Gonzalez A; Schiller JH; Carbone DP
J Thorac Oncol; 2010 Feb; 5(2):169-78. PubMed ID: 20035238
[TBL] [Abstract][Full Text] [Related]
17. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Lee JH; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Lee KS
Cancer Imaging; 2016 Mar; 16():5. PubMed ID: 26984681
[TBL] [Abstract][Full Text] [Related]
18. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma.
Yamaguchi T; Yanagisawa K; Sugiyama R; Hosono Y; Shimada Y; Arima C; Kato S; Tomida S; Suzuki M; Osada H; Takahashi T
Cancer Cell; 2012 Mar; 21(3):348-61. PubMed ID: 22439932
[TBL] [Abstract][Full Text] [Related]
19. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?
Zhang Y; Li XY; Tang Y; Xu Y; Guo WH; Li YC; Liu XK; Huang CY; Wang YS; Wei YQ
Lung Cancer; 2013 Aug; 81(2):302-5. PubMed ID: 23683536
[TBL] [Abstract][Full Text] [Related]
20. Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
Hellmann MD; Reva B; Yu H; Rusch VW; Rizvi NA; Kris MG; Arcila ME
J Thorac Oncol; 2014 Oct; 9(10):e73-4. PubMed ID: 25521405
[No Abstract] [Full Text] [Related]
[Next] [New Search]
